Newsroom | 12273 results
Sorted by: Latest
-
Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision
JACKSONVILLE, Fla.--(BUSINESS WIRE)--Johnson & Johnson showcases new clinical data for TECNIS PureSee IOL demonstrating excellent contrast sensitivity and extended range of vision...
-
Retractable Technologies, Inc. Announces Workforce Reduction
LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE American: RVP) reports that it has reduced its workforce by approximately 16%. The reduction is expected to save an estimated $2.2 million in annual wages and employment benefits, or approximately 13% of total estimated workforce costs. The expected savings are offset by estimated one-time separation payments of approximately $122 thousand to the affected workers. Approximately 58% of the targeted payroll reduction affects...
-
BoxSPINE Receives FDA Clearance for Rodless Spinal Fixation System, Redefining a Decades-Old Surgical Approach
WINONA LAKE, Ind. & PLYMOUTH, Ind.--(BUSINESS WIRE)--BoxSPINE Receives FDA Clearance for Rodless Spinal Fixation System, The DUET™ Spinal Fixation System, Redefining a Decades-Old Surgical Approach....
-
Orthofix Realigns Spine Leadership to Strengthen Focus and Execution
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced a strategic realignment of its Spine leadership team designed to accelerate profitable growth and sharpen execution across its commercial and innovation priorities. The Company also reported preliminary, unaudited net sales results for the first quarter ended March 31, 2026. Spine Leadership Realignment To accelerate decision-making, sharpen leadership accountabi...
-
Teleflex Announces Governance Updates
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced several Board and governance updates, including the nomination of Michael J. Tokich to the Board of Directors, its intent to establish a new Growth and Operating Committee of the Board and its plan to commence share repurchases under the Company’s previously announced program ahead of schedule. The announcements reflect the Board’s continued focus on strong governanc...
-
STAAR Surgical Announces Preliminary Net Sales for First Quarter 2026
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced preliminary net sales for the first quarter ended April 3, 2026. STAAR is announcing its preliminary net sales in advance of its quarterly earnings announcement because it expects to be interacting with members of the investment community, as well as with surgeons and other members of t...
-
Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release first quarter 2026 financial results after the market close on Wednesday, April 29, 2026. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on April 29, 2026. A link to t...
-
Bausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+™ Dual-Port Vitrectomy Cutter and Adaptive Fluidics™ Advanced Update
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Bi-Blade+ advanced dual-port vitrectomy cutter and the Adaptive Fluidics advanced update on the Stellaris Elite® Vision Enhancement System. “Retinal surgeons who are familiar with our Bi-Blade technology understand the benefits of it...
-
New Clinical Data on Fish-Skin Grafts to Headline Kerecis Presence at SAWC Spring
CHARLOTTE, N.C.--(BUSINESS WIRE)--Kerecis will present data at SAWC Spring 2026 showing fish-skin grafts are superior to standard care for treating severe Stage 3 and 4 pressure ulcers...
-
Endospan Receives FDA Approval for the NEXUS® Aortic Arch Stent Graft System
TEL AVIV, Israel--(BUSINESS WIRE)--Endospan, a privately-held company pioneering solutions for the endovascular repair of aortic arch disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the NEXUS® Aortic Arch Stent Graft. FDA approval was supported by the one-year results of the TRIOMPHE Investigational Device Exemption (IDE) Study evaluating the NEXUS® System shown to effectively treat aortic arch disease, including chronic aortic dissections, in patients at...